HIV に感染した H9 T 細胞の走査型電子顕微鏡写真。 国際研究により、シュラーフェン 12 (SLFN 12) が、ウイルスタンパク質の産生を妨害し、ウイルス感染細胞が抗 HIV 療法や免疫反応を回避するのを助ける新規の HIV 制限因子であることが特定されました。 このタンパク質、SLFN 12 はロイシン-UUA tRNA を特異的に切断します。ロイシン UUA tRNA は、HIV ウイルスタンパク質の産生には必須ですが、細胞タンパク質には必須ではありません。 この発見は、潜在的に感染している細胞を標的とすることでHIV感染を治癒するための新たな治療戦略につながる可能性がある。 SLFN 12 の抗ウイルス機能をブロックすることで、宿主の免疫系と抗ウイルス薬はウイルスの貯蔵庫をより効果的に排除し、潜在的な感染細胞を根絶できる可能性があります。 クレジット: NIAID
MELIS-UPFの研究者アンドレアス・マイヤーハンス氏とフアナ・ディエス氏がコーディネートした国際研究で、感染症を治すための新たな戦略への道を開く可能性のある新たなHIV制限因子であるシュラーフェン12が特定された。
研究者らは、ウイルスタンパク質の生成を妨害し、[{” attribute=””>virus-infected cells evade treatment. This discovery could lead to improved therapeutic strategies for curing HIV infections by targeting and eliminating latently infected cells.
An international study led by MELIS-UPF researchers from the Infection Biology and Molecular Virology laboratories has identified and characterized Schlafen 12 (SLFN 12) as a novel HIV restriction factor. SLFN 12 shuts down viral protein production and helps virus-infected cells to escape from anti-HIV therapy and immune responses. These findings pave the way for improving therapeutic strategies that aim to cure HIV infections.
Schlafen is a German word meaning “sleeping” that gives its name to a family of proteins involved in cancer, drug sensitivity and antiviral functions.
Human Immunodeficiency Virus (HIV) infections, if left untreated, lead to the gradual destruction of the immune system, AIDS, in its final stages. Worldwide, some 650,000 individuals die of AIDS each year, making it a major threat to human health. Nonetheless, despite there being no general cure for an established infection, appropriate antiretroviral therapy enables people living with HIV to lead a relatively healthy life. Unfortunately, once treatment is stopped, the virus returns from a reservoir of latently infected cells.
“Latency is a major barrier impairing virus elimination in HIV-infected individuals. We will not be able to cure an existing infection until we will get rid of latently infected cells. This is why it is essential to understand how latency works,” explains Andreas Meyerhans, ICREA research professor at UPF who has coordinated the study together with Juana Díez.
Graphical abstract of Shclafen 12 activity. Credit: Pompeu Fabra University
The paper, published today (May 10) in the journal Communication Biology, has identified and characterized SLFN12, a protein that restricts the production of viral proteins by cleaving specific cellular tRNAs, the building blocks for protein construction. As a consequence, in the presence of active SLFN12, HIV-infected CD4 T cells are not able to complete the virus production process but keep its templates, HIV RNA, in a latent state.
“SLFN12 impairs protein production, restricting the production of viral particles. Such cells are latently infected, invisible to the immune system and anti-HIV therapies,” says Mie Kobayashi-Ishihara, first author of the manuscript.
The study also reveals how SLFN12 can specifically inhibit HIV protein production without blocking cellular protein production. “SLFN12 cleaves Leucine-UUA tRNA, a building block that is rarely used for cellular proteins but essential for HIV viral proteins,” Juana Díez explains.
This finding opens the possibility to design new therapeutic strategies against HIV. “Blocking SLFN12 antiviral functions should increase viral protein expression and thus, enable the host immune system and antiviral drugs to better eliminate viral reservoirs. Once you start producing the virus, it becomes visible again. You get your target back. So, you can attack it, and hopefully, definitely eliminate the latent infected cells,” concludes Meyerhans.
Reference: “Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells” by Kobayashi-Ishihara, M at al., 10 May 2023, Communication Biology.
DOI: 10.1038/s42003-023-04841-y
Funding: Takeda Science Foundation, JSPS Oversea Research Fellowship, MINECO, FEDER, Miguel Servet program by ISCIII, Horizon 2020 Framework Programme, NIH/National Institutes of Health, Spanish Ministry of Science and Innovation, “María de Maeztu” Programme for Units of Excellence in R&D, ISCIII/MINECO and FEDER